Aurinia Pharmaceuticals Inc (AUPH) |
|
Price: $5.0900
$-0.08
-1.547%
|
Day's High:
| $5.22
| Week Perf:
| -2.12 %
|
Day's Low: |
$ 5.06 |
30 Day Perf: |
-15.45 % |
Volume (M): |
1,267 |
52 Wk High: |
$ 12.43 |
Volume (M$): |
$ 6,449 |
52 Wk Avg: |
$8.98 |
Open: |
$5.18 |
52 Wk Low: |
$4.98 |
|
|
Market Capitalization (Millions $) |
735 |
Shares
Outstanding (Millions) |
144 |
Employees |
71 |
Revenues (TTM) (Millions $) |
176 |
Net Income (TTM) (Millions $) |
-78 |
Cash Flow (TTM) (Millions $) |
-45 |
Capital Exp. (TTM) (Millions $) |
1 |
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that focuses on the development of novel therapies for the treatment of lupus nephritis and other autoimmune diseases. The company is headquartered in Victoria, British Columbia, Canada, and was founded in 199
The companyes flagship drug candidate is voclosporin, which is a calcineurin inhibitor under development for the treatment of lupus nephritis. Lupus nephritis is a serious autoimmune disease that affects the kidneys and can lead to kidney failure. Currently, there are no FDA-approved treatments for lupus nephritis.
Aurinia is conducting a Phase 3 clinical trial of voclosporin in lupus nephritis, which is expected to be completed in 202 The company has also conducted Phase 2 trials of voclosporin in other autoimmune diseases, including dry eye syndrome and non-infectious uveitis.
In addition to voclosporin, Aurinia is developing a pipeline of other novel therapies for autoimmune diseases. The companyes pipeline includes drugs that target the complement system, a complex system of proteins that play a role in immune response and inflammation.
Aurinia has a strong intellectual property (IP) portfolio, including patents related to the composition of matter and the use of voclosporin and other compounds for the treatment of autoimmune diseases. The company has also formed strategic partnerships with other biopharmaceutical companies to develop and commercialize its drug candidates.
Aurinia has a talented and experienced management team, including CEO Peter Greenleaf, who has over 20 years of experience in the pharmaceutical industry. The company also has a strong financial position, with over $400 million in cash and investment securities as of December 31, 2020.
Overall, Aurinia Pharmaceuticals Inc. is a leading biopharmaceutical company focused on the development of novel therapies for the treatment of lupus nephritis and other autoimmune diseases. With a strong pipeline of drug candidates, a robust IP portfolio, and a talented management team, Aurinia is well-positioned to make a meaningful impact in the field of autoimmune diseases.
Company Address: #140, 14315 - 118 Avenue Edmonton 0 AB
Company Phone Number: 744-2487 Stock Exchange / Ticker: NASDAQ AUPH
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) recently announced its fourth-quarter and full-year business performance for 2023, along with a strategic review update. The company has outlined its plans to enhance shareholder value by focusing exclusively on the commercial execution of its LUPKYNIS (voclosporin) business and implementing a significant share repurchase program. In terms of financials, Aurinia reported a loss per share of $-0.18 for the fiscal period ending December 31, 2023, compared to $-0.17 in the previous year. The loss also surged from $-0.09 per share from the previous quarter. On the other hand, the company's revenue displayed robust growth, increasing by 58.59% to $45.10 million from $28.44 million in the corresponding quarter of the previous year. However, sequentially, revenue fell by -17.28% from $54.52 million.
|
Aurinia Pharmaceuticals Inc
The stock market is a dynamic and ever-changing environment, where investors closely monitor companies' financial performance in order to make informed decisions. In the third quarter of the 2023 earnings season, Aurinia Pharmaceuticals Inc faced some challenges that led to weakening orders and subsequent losses. However, it is important to view these results in context and consider the overall trajectory of the company. During this reporting period, revenue for Aurinia Pharmaceuticals Inc declined by -2.266%, reaching $54.52 million. Additionally, the shortfall per share increased to $-0.09, compared to $-0.06 per share in the same period the previous year. These figures indicate a deterioration of the company's top-line when compared to its peers in the Major Pharmaceutical Preparations sector, as they reported revenue gains during the same period.
|
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc, a major player in the pharmaceutical preparations industry, has shown positive growth in several key areas, according to their recent financial reports. For the fiscal year ending June 30, 2023, the company reported a decrease in loss per share, from $-0.25 to $-0.08, compared to the previous year. Additionally, the company's earnings per share (EPS) improved from $-0.18 to $-0.08 during the same reporting period. One of the most notable achievements for Aurinia Pharmaceuticals Inc is the significant increase in revenue. Their revenue jumped by an impressive 47.189% to $41.49 million, compared to $28.19 million in the previous year. This demonstrates a strong performance and suggests that the company is growing at a faster rate than its industry counterparts. In fact, during the second quarter of 2023, two-thirds of major pharmaceutical preparations companies experienced an average top-line improvement of only 1.81% compared to the previous year.
|
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, recently reported their financial results for the most recent fiscal period, showing a decrease in their net loss from the previous year. The company reported a net loss of $-0.18 per share, compared to $-0.27 from the prior year. However, the shortfall increased from $-0.17 per share in the prior quarter. Despite the decrease in net loss per share, there was significant revenue growth for Aurinia Pharmaceuticals. The company reported revenue of $34.41 million, representing a 59.117% increase from the corresponding quarter a year ago. The sequentially revenue also improved by 21.009% from $28.44 million. These growth figures are impressive, and the strong revenue growth points to the success of Aurinia Pharmaceuticals' business strategy.
|
Per Share |
Current |
Earnings (TTM) |
-0.53 $ |
Revenues (TTM) |
1.21 $
|
Cash Flow (TTM) |
- |
Cash |
-
|
Book Value |
2.62 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.53 $
|
Revenues (TTM) |
1.21 $ |
Cash Flow (TTM) |
- |
Cash |
-
|
Book Value |
2.62 $ |
Dividend (TTM) |
0 $ |
|
|
|
Company Estimates |
|
|
• Revenue Outlook
Aurinia Pharmaceuticals Inc does not provide revenue guidance.
• Earnings Outlook
Aurinia Pharmaceuticals Inc does not provide earnings estimates.
|
|
|
|
|
|